Myriad Genetics (MYGN) News Today

Maven Securities LTD bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company's stock, valued at

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 94,624 shares of the company's stock, valued at approximately $2

Point72 Asset Management L.P. lifted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 7.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 839,456 shares of the company's stock

D. E. Shaw & Co. Inc. reduced its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 11.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,126,747 shares of the company's stock af

Dimensional Fund Advisors LP raised its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 2.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,776,959 shares of the company's stock after

Point72 Asset Management L.P. grew its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 7.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 839,456 shares of the company's stock afte

Earnest Partners LLC increased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 3.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,072,018 shares of the company's stock after acquiring an additional 13

Sei Investments Co. increased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 5.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,417,192 shares of the company's stock after purchasing an

Morgan Stanley assumed coverage on shares of Myriad Genetics in a research note on Thursday. They set an "equal weight" rating and a $32.00 target price on the stock.

Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year High at $29.30

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has earned a consensus rating of "Hold" from the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven

Myriad Genetics (NASDAQ:MYGN) Stock Price Down 4.9%

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director Heinrich Dreismann sold 10,000 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $27.05, for a total transaction of $270,500.00. Following the completion of the sale, the director now owns 121,648 shares in the company, valued at $3,290,578.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Natixis Advisors LLC raised its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 15.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 275,367 shares of the company's stock after buying an additional

Myriad Genetics (NASDAQ:MYGN) Shares Up 4.7%

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director Colleen F. Reitan sold 46,012 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the transaction, the director now directly owns 42,533 shares of the company's stock, valued at $1,188,797.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Myriad Genetics (NASDAQ:MYGN) Shares Down 3.2%

Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month High at $29.08

Wells Fargo & Company began coverage on Myriad Genetics in a research note on Tuesday. They set an "overweight" rating and a $35.00 target price on the stock.

Legato Capital Management LLC purchased a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 45,916 shares of the company's stock, valued at approx

Myriad Genetics (NASDAQ:MYGN) Shares Gap Up to $27.64

Assenagon Asset Management S.A. boosted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 26.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,524 shares of the company's s

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has earned an average recommendation of "Hold" from the eleven brokerages that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommend

Scotiabank boosted their price objective on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a "sector outperform" rating in a research report on Tuesday.

Tidal Investments LLC bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 28,432 shares of the company's stock, valued at appr

TD Cowen raised their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a "hold" rating in a report on Wednesday.